Navigation Links
EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus
Date:11/6/2009

VIENNA, Austria, November 6 /PRNewswire/ -- EUCODIS Bioscience, a company developing, customizing, manufacturing, and marketing enzymes for the chemical industry announced today that it has entered into a research agreement with Bio Sidus, the leading biopharmaceutical company in Latin America.

The agreement gives EUCODIS Bioscience exclusive access - for the search of enzymes of interest - to Bio Sidus' proprietary collection of psychrophilic bacteria strains and other organisms isolated from the Antarctic and the surrounding oceans. Psychrophiles are organisms that thrive at low temperatures. EUCODIS Bioscience will use its experience in enzyme development to screen the strains for enzymatic activities that can be used in industrial and other commercial applications.

"We are excited that EUCODIS Bioscience gains access to Bio Sidus' collection of psychrophilic microorganisms with their wealth of hitherto untapped biological diversity," commented Rudy Pandjaitan, PhD, CEO of EUCODIS Bioscience.

"The biological diversity of organisms that are adapted to an extremely cold environment offers a huge potential for the discovery and development of novel enzymes. Enzymes that enable or accelerate chemical processes at a low temperature offer tremendous commercial and environmental advantages for energy-intensive industrial processes as well as for detergents and other products for domestic applications."

About EUCODIS Bioscience

EUCODIS Bioscience GmbH develops, optimizes, manufactures, and markets industrial enzymes.

EUCODIS Bioscience' products help customers in the chemical, pharmaceutical, and food and feed industries to make manufacturing processes more efficient and cleaner, and to generate products with superior properties.

EUCODIS Bioscience originally focused on developing enzymes for industrial partners, including GlaxoSmithKline, Henkel, and Lohmann Animal Health. Since 2009, the Company also markets its own products.

Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with subsidiaries in France and Germany.

For more information, please visit http://www.eucodisbioscience.com

About Bio Sidus

Bio Sidus is the leading biopharmaceutical company in Latin America. Bio Sidus currently manufactures and markets human erythropoietin, human growth hormone and human interferon Alfa 2a and 2b, amongst other proprietary biotech developments. The company is part of Grupo Sidus, a leading developer and manufacturer and pharmaceuticals, active pharmaceutical ingredients (APIs) and biopharmaceuticals that are marketed in more than 90 countries. Bio Sidus is based in Buenos Aires, Argentina, and has 250 employees.

    Company contact EUCODIS Bioscience:
    Rudy Pandjaitan, PhD
    CEO
    EUCODIS Bioscience
    Campus Vienna Biocenter II
    Viehmarktgasse 2 a/ 2 OG
    A-1030 Vienna
    AUSTRIA
    +43-1-8900804
    office@eucodisbioscience.com

    Media contact EUCODIS Bioscience:
    Frank Butschbacher
    Investor Relations & Communications
    http://www.butschbacher.net
    +43-650-7844940
    office@butschbacher.net


SOURCE EUCODIS Bioscience


'/>"/>
SOURCE EUCODIS Bioscience
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EUCODIS Bioscience Launches Lipase Portfolio
2. EUCODIS Bioscience Launches Beta-Lactamase for Antibiotics and Diagnostics Industries
3. EUCODIS Bioscience Signs Research Agreement With Genencor
4. EUCODIS Bioscience and Lohmann Animal Health Announce Achievement of Major Development Milestone
5. EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer
6. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
7. YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009
8. YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG
9. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
10. eBioscience Acquires Bender MedSystems; Business Combination Adds Cutting-Edge Product Lines and Expands International Operations
11. Ohio Bioscience Industry Leads Midwest, Among Best in Nation as Investment Destination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... , ... July 17, 2017 , ... ... Weihong Hsing, Ph.D. , recently participated in the BiG (Biomedical Innovation Group) annual ... dominated by discussions of CAR-T (chimeric antigen receptor T-cell) therapy, a rapidly developing ...
(Date:7/16/2017)... ... July 16, 2017 , ... ... instruments announced the launch of its new line of Extreme Environment Shakers today. ... that require CO2 and humidity for optimal cell growth such as cell cultures, ...
(Date:7/14/2017)... (PRWEB) , ... July 13, 2017 , ... ... linearity and calibration verification test kit has received US FDA 510 (k) clearance ... a human plasma matrix, evaluates D-Dimer. Each VALIDATE® D-Dimer kit, prepared using the ...
(Date:7/13/2017)... ... July 13, 2017 , ... In’Tech Medical ... has announced today the completion of a major transaction with Eurazeo PME. The ... external growth. The alliance fuels In’Tech Medical’s service offerings while leveraging the company’s ...
Breaking Biology Technology:
(Date:3/22/2017)...   Neurotechnology , a provider of high-precision ... the release of the SentiVeillance 6.0 ... recognition using up to 10 surveillance, security and ... new version uses deep neural-network-based facial detection and ... a Graphing Processing Unit (GPU) for enhanced speed. ...
(Date:3/22/2017)... Vigilant Solutions , a vehicle location ... announced today the appointment of retired FBI special agent ... business development. Mr. Sheridan brings more than ... focus on the aviation transportation sector, to his new ... Sheridan served as the Aviation Liaison Agent Coordinator (ALAC) ...
(Date:3/20/2017)... -- PMD Healthcare announces the release of its new ... (WMS), a remote, real-time lung health monitoring and management ... a Medical Device, Digital Health, and Chronic Care Management ... solutions that empower people to improve their healthcare and ... the first ever personal spirometer, Spiro PD, which was ...
Breaking Biology News(10 mins):